ClinicalTrials.gg
CompletedNCT01664598Updated Dec 11, 2023Results posted

An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis

A Phase 3 interventional study of Tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 12 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-11.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
78th of 110
49 · median 97
Started
2012
with 10 others
Phase 3
65 of 110
none open now
Registered
64th of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 78th largest by enrollment, is one of 11 that started in 2012, is one of 65 in phase 3, and was the 64th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This open-label, single arm, multicenter long-term extension study of WA19926 evaluated the safety and efficacy of tocilizumab (RoActemra/Actemra) in participants with moderate to severe rheumatoid arthritis who completed the 104-week WA19926 core study. Eligible patients received tocilizumab 8 mg/kg intravenously every 4 weeks for up to 104 weeks.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants, >/= 18 years of age
  • Participants who complete their last WA19926 core study visit (Week 104) and who may benefit from study drug treatment according to the Investigator's assessment
  • No current or recent adverse event or laboratory finding preventing the use of the study drug dose of RoActemra/Actemra 8 mg/kg at baseline visit
  • Women of must agree to use adequate as defined by protocol during the treatment period

Exclusion criteria

Exclusion Criteria:

  • Pregnant females
  • Participants who have withdrawn prematurely from the WA19926 core study for any reason
  • Treatment with any agent or cell-depleting therapies since the last administration of study drug in WA19926
  • Treatment with an anti-tumor necrosis factor (TNF) or anti-interleukin (IL) 1 agent, or a T-cell costimulation modulator since the last administration of study drug in WA19926
  • Immunization with a live/attenuated vaccine since the last administration of study drug in WA19926
  • Diagnosis since last WA19926 visit (Week 104) of rheumatic disease other than rheumatoid arthritis
  • Diagnosis since last WA19926 visit (Week 104) of inflammatory joint disease other than rheumatoid arthritis
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies, including tocilizumab and its
  • Evidence of severe uncontrolled concomitant disease or disorder
  • Known active or history of recurrent infections
  • Active tuberculosis requiring treatment in the previous 3 years
  • History of alcohol, drug or chemical abuse since inclusion in the WA19926 study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Tocilizumab

    Drug: Tocilizumab

Interventions

  • 8 mg/kg administered intravenously (IV) every 4 weeks for 104 weeks

    Also known as: RoActemra, Actemra

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESIs)

    An AE is any untoward medical occurrence in a study participant given administered a pharmaceutical product, regardless of the cause of the AE. A SAE was any experience that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant. AESIs included serious infections (including opportunistic infections) and abnormal liver function tests.

    Time frame: Up to 112 weeks

  2. Percentage of Adverse Events (AEs) Leading to Dose Modification and AEs Leading to Study Withdrawal

    An AE is any untoward medical occurrence in a study participant given administered a pharmaceutical product, regardless of the cause of the AE.

    Time frame: Up to 112 weeks

  3. Percentage of Adverse Events With Severity as Mild, Moderate, and Severe

    Time frame: Up to 112 weeks

Secondary outcomes

  1. Percent Change From Baseline in the Disease Activity Index 28 Erythrocyte Sedimentation Rate (DAS28-ESR) Over Time

    The DAS28-ESR Scale is a measure of a participant's disease activity. It is based on tender joint count (28 joints), swollen joint count (28 joints), a participant's assessment of disease activity, and erythrocyte sedimentation rate. DAS28-ESR is expressed as a score on a scale with a minimum score of 0 (low disease activity ) to a maximum score of 10 (high disease activity). A negative mean percent change from baseline indicates a decrease in disease activity, and a positive mean percent change from baseline indicates an increase in disease activity.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104

  2. Percent Change From Baseline in the Simplified Disease Activity Index (SDAI) Over Time

    The Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: tender joint count (TJC) and swollen joint count (SJC), based on a 28-joint assessment, patient and physician global assessment assessed on 0-10 centimeter (cm) visual analogue scale (VAS), where 0 = no disease activity and 10 = worst disease activity, and level of C-reactive protein (CRP, mg/dL). SDAI total score = 0-86. SDAI \<=3.3 indicates clinical remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity. A negative mean percent change from baseline indicates a decrease in disease activity, and a positive mean percent change from baseline indicates an increase in disease activity.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104

  3. Change From Baseline in Tender Joint Count 66 (TJC 66) Over Time

    Number of tender joints was determined by examination of 66 joints, as assessed through pressure and passive joint motion during physical examination.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104

  4. Change From Baseline in Swollen Joint Count 66 (SJC 66) Over Time

    Number of swollen joints was determined by examination of 66 joints, as assessed through pressure and passive joint motion during physical examination.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104

  5. Percentage of Participants With Treatment-Free Remission According to DAS28-ESR/SDAI Remission Criteria

    Treatment-free remission is remission at two consecutive assessment visits (every 12 weeks) after discontinuing study drug on the second assessment visit. Clinical remission is DAS28-ESR score \<2.6 and/or SDAI score ≤3.3. The DAS28-ESR scale is a measure of a participant's disease activity based on tender joint count (28 joints), swollen joint count (28 joints), a participant's assessment of disease activity, and ESR. DAS28-ESR scored on a scale with a minimum score of 0 (low disease activity) to a maximum score of 10 (high disease activity). The SDAI is sum of TJC and SJC, based on a 28-joint assessment, patient and physician global assessment assessed on 0-10 centimeter visual analogue scale (VAS), where 0 = no disease activity and 10 = worst disease activity, and level of C-reactive protein (CRP, mg/dL). SDAI total score = 0-86. SDAI \<=3.3 indicates clinical remission, \>3.4 to 11=low disease activity, \>11 to 26=moderate disease activity, and \>26=high (or severe) disease activity.

    Time frame: Up to 104 weeks

  6. Time to Rheumatoid Arthritis Recurrence in Participants Who Achieved Treatment-Free Remission

    Time to rheumatoid arthritis (RA) recurrence = period from treatment-free remission to RA recurrence. RA recurrence was worsening of disease activity with treatment beyond supportive therapy.

    Time frame: Up to 104 weeks

  7. Percent Change in Participant's General Assessment of Disease Activity (Severity of Disease) VAS Over Time

    The participant's overall assessment of their current disease activity was displayed on a 100-millimeter (mm) horizontal VAS. The left-hand extreme (0 mm) of the line was described as "no disease activity" (symptom free and no arthritis symptoms) and the right-hand extreme (100 mm) was described as "maximum disease activity" (maximum arthritis disease activity). The change in Patient Global Assessment of Disease Activity was determined as the difference in values from baseline at each visit.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104

  8. Percent Change in Participant's Assessment of Pain (VAS) Over Time

    Participants' pain was assessed using a 10-mm horizontal VAS (0 to 10 mm) where 0=pain absent and 10=intolerable pain. Participants responded by placing a mark on the line to indicate their current level of pain; the distance from the left edge to the mark was recorded.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104

  9. Change From Baseline in Health Assessment Questionnaire (HAQ-DI) Score Over Time

    The HAQ-DI was used to assess the physical ability and functional status of participants as well as quality of life. The disability dimension consists of 20 multiple choice items concerning difficulty in performing 8 common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and activities. Participants choose from 4 response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104

07

Results

Posted Dec 11, 2023

Participant flow

Participant flow — Overall Study
MilestoneTocilizumab
Started49
Completed43
Not completed6
Withdrew: Sponsor decision1
Withdrew: Withdrawal of informed consent4
Withdrew: Adverse event1

Outcome measures

PrimaryPercentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESIs)

An AE is any untoward medical occurrence in a study participant given administered a pharmaceutical product, regardless of the cause of the AE. A SAE was any experience that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant. AESIs included serious infections (including opportunistic infections) and abnormal liver function tests.

Time frame:
Up to 112 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESIs)
percentage of participantsTocilizumab
Adverse Events69.4
SAEs10.2
AESIs17.2
PrimaryPercentage of Adverse Events (AEs) Leading to Dose Modification and AEs Leading to Study Withdrawal

An AE is any untoward medical occurrence in a study participant given administered a pharmaceutical product, regardless of the cause of the AE.

Time frame:
Up to 112 weeks
Reported as:
Number · percentage of adverse events
Percentage of Adverse Events (AEs) Leading to Dose Modification and AEs Leading to Study Withdrawal
percentage of adverse eventsTocilizumab
AEs Leading to Dose Modification34.5
AEs Leading to Study Withdrawal1.1
PrimaryPercentage of Adverse Events With Severity as Mild, Moderate, and Severe
Time frame:
Up to 112 weeks
Reported as:
Number · percentage of adverse events
Percentage of Adverse Events With Severity as Mild, Moderate, and Severe
percentage of adverse eventsTocilizumab
Mild62.1
Moderate36.8
Severe1.1
SecondaryPercent Change From Baseline in the Disease Activity Index 28 Erythrocyte Sedimentation Rate (DAS28-ESR) Over Time

The DAS28-ESR Scale is a measure of a participant's disease activity. It is based on tender joint count (28 joints), swollen joint count (28 joints), a participant's assessment of disease activity, and erythrocyte sedimentation rate. DAS28-ESR is expressed as a score on a scale with a minimum score of 0 (low disease activity ) to a maximum score of 10 (high disease activity). A negative mean percent change from baseline indicates a decrease in disease activity, and a positive mean percent change from baseline indicates an increase in disease activity.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104
Reported as:
Mean · percent change
Percent Change From Baseline in the Disease Activity Index 28 Erythrocyte Sedimentation Rate (DAS28-ESR) Over Time
percent changeTocilizumab
Change at Week 12 (n=42)-35.4 ± 30.4
Change at Week 24 (n=40)-27.2 ± 35.4
Change at Week 36 (n=39)-29.3 ± 48.4
Change at Week 48 (n=33)-24.6 ± 41.0
Change at Week 56 (n=34)-32.5 ± 31.9
Change at Week 68 (n=32)-38.3 ± 25.6
Change at Week 80 (n=28)-29.4 ± 33.5
Change at Week 92 (n=22)-26.9 ± 30.9
Change at Week 104 (n=26)-38.1 ± 25.9
SecondaryPercent Change From Baseline in the Simplified Disease Activity Index (SDAI) Over Time

The Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: tender joint count (TJC) and swollen joint count (SJC), based on a 28-joint assessment, patient and physician global assessment assessed on 0-10 centimeter (cm) visual analogue scale (VAS), where 0 = no disease activity and 10 = worst disease activity, and level of C-reactive protein (CRP, mg/dL). SDAI total score = 0-86. SDAI \<=3.3 indicates clinical remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity. A negative mean percent change from baseline indicates a decrease in disease activity, and a positive mean percent change from baseline indicates an increase in disease activity.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104
Reported as:
Mean · percent change
Percent Change From Baseline in the Simplified Disease Activity Index (SDAI) Over Time
percent changeTocilizumab
Change at Week 12 (n=37)-45.5 ± 33.9
Change at Week 24 (n=36)-34.7 ± 45.6
Change at Week 36 (n=38)-6.3 ± 221.1
Change at Week 48 (n=36)-12.4 ± 84.3
Change at Week 56 (n=34)-39.3 ± 66.4
Change at Week 68 (n=35)-47.3 ± 39.6
Change at Week 80 (n=36)-30.3 ± 66.9
Change at Week 92 (n=36)-12.5 ± 140.1
Change at Week 104 (n=35)-28.8 ± 115.7
SecondaryChange From Baseline in Tender Joint Count 66 (TJC 66) Over Time

Number of tender joints was determined by examination of 66 joints, as assessed through pressure and passive joint motion during physical examination.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104
Reported as:
Mean · tender joints
Change From Baseline in Tender Joint Count 66 (TJC 66) Over Time
tender jointsTocilizumab
Change at Week 12 (n=49)-5.0 ± 6.7
Change at Week 24 (n=47)-5.7 ± 9.5
Change at Week 36 (n=47)-6.6 ± 10.4
Change at Week 48 (n=46)-6.2 ± 11.8
Change at Week 56 (n=44)-6.7 ± 10.6
Change at Week 68 (n=45)-6.6 ± 10.6
Change at Week 80 (n=45)-6.2 ± 10.8
Change at Week 92 (n=43)-6.3 ± 11.9
Change at Week 104 (n=43)-7.4 ± 10.9
SecondaryChange From Baseline in Swollen Joint Count 66 (SJC 66) Over Time

Number of swollen joints was determined by examination of 66 joints, as assessed through pressure and passive joint motion during physical examination.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104
Reported as:
Mean · swollen joints
Change From Baseline in Swollen Joint Count 66 (SJC 66) Over Time
swollen jointsTocilizumab
Change at Week 12 (n=49)-3.5 ± 7.9
Change at Week 24 (n=47)-3.7 ± 8.2
Change at Week 36 (n=47)-4.5 ± 9.9
Change at Week 48 (n=46)-4.6 ± 9.9
Change at Week 56 (n=44)-4.7 ± 9.7
Change at Week 68 (n=45)-4.9 ± 9.7
Change at Week 80 (n=45)-4.6 ± 9.7
Change at Week 92 (n=43)-4.3 ± 10.2
Change at Week 104 (n=43)-5.0 ± 10.0
SecondaryPercentage of Participants With Treatment-Free Remission According to DAS28-ESR/SDAI Remission Criteria

Treatment-free remission is remission at two consecutive assessment visits (every 12 weeks) after discontinuing study drug on the second assessment visit. Clinical remission is DAS28-ESR score \<2.6 and/or SDAI score ≤3.3. The DAS28-ESR scale is a measure of a participant's disease activity based on tender joint count (28 joints), swollen joint count (28 joints), a participant's assessment of disease activity, and ESR. DAS28-ESR scored on a scale with a minimum score of 0 (low disease activity) to a maximum score of 10 (high disease activity). The SDAI is sum of TJC and SJC, based on a 28-joint assessment, patient and physician global assessment assessed on 0-10 centimeter visual analogue scale (VAS), where 0 = no disease activity and 10 = worst disease activity, and level of C-reactive protein (CRP, mg/dL). SDAI total score = 0-86. SDAI \<=3.3 indicates clinical remission, \>3.4 to 11=low disease activity, \>11 to 26=moderate disease activity, and \>26=high (or severe) disease activity.

Time frame:
Up to 104 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Free Remission According to DAS28-ESR/SDAI Remission Criteria
percentage of participantsTocilizumab
Percentage of Participants With Treatment-Free Remission According to DAS28-ESR/SDAI Remission Criteria71.4
SecondaryTime to Rheumatoid Arthritis Recurrence in Participants Who Achieved Treatment-Free Remission

Time to rheumatoid arthritis (RA) recurrence = period from treatment-free remission to RA recurrence. RA recurrence was worsening of disease activity with treatment beyond supportive therapy.

Time frame:
Up to 104 weeks
Reported as:
Median · weeks
Time to Rheumatoid Arthritis Recurrence in Participants Who Achieved Treatment-Free Remission
weeksTocilizumab
Time to Rheumatoid Arthritis Recurrence in Participants Who Achieved Treatment-Free Remission23 (17.6 to 28.4)
SecondaryPercent Change in Participant's General Assessment of Disease Activity (Severity of Disease) VAS Over Time

The participant's overall assessment of their current disease activity was displayed on a 100-millimeter (mm) horizontal VAS. The left-hand extreme (0 mm) of the line was described as "no disease activity" (symptom free and no arthritis symptoms) and the right-hand extreme (100 mm) was described as "maximum disease activity" (maximum arthritis disease activity). The change in Patient Global Assessment of Disease Activity was determined as the difference in values from baseline at each visit.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104
Reported as:
Mean · percent change
Percent Change in Participant's General Assessment of Disease Activity (Severity of Disease) VAS Over Time
percent changeTocilizumab
Change at Week 12 (n=48)-19.6 ± 45.7
Change at Week 24 (n=46)-20.3 ± 49.8
Change at Week 36 (n=46)-17.5 ± 60.6
Change at Week 48 (n=45)6.1 ± 92.8
Change at Week 56 (n=43)-14.2 ± 63.8
Change at Week 68 (n=44)-19.3 ± 48.6
Change at Week 80 (n=44)-9.2 ± 58.1
Change at Week 92 (n=43)-4.7 ± 67.2
Change at Week 104 (n=42)-14.2 ± 75.7
SecondaryPercent Change in Participant's Assessment of Pain (VAS) Over Time

Participants' pain was assessed using a 10-mm horizontal VAS (0 to 10 mm) where 0=pain absent and 10=intolerable pain. Participants responded by placing a mark on the line to indicate their current level of pain; the distance from the left edge to the mark was recorded.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104
Reported as:
Mean · percent change
Percent Change in Participant's Assessment of Pain (VAS) Over Time
percent changeTocilizumab
Change at Week 12 (n=48)-21.8 ± 43.2
Change at Week 24 (n=46)-20.3 ± 44.9
Change at Week 36 (n=46)-25.4 ± 50.0
Change at Week 48 (n=45)4 ± 131.4
Change at Week 56 (n=43)-19.8 ± 66.3
Change at Week 68 (n=44)-19.9 ± 57.6
Change at Week 80 (n=44)-17.1 ± 54.2
Change at Week 92 (n=43)-10.9 ± 59.2
Change at Week 104 (n=42)-20.5 ± 61.3
SecondaryChange From Baseline in Health Assessment Questionnaire (HAQ-DI) Score Over Time

The HAQ-DI was used to assess the physical ability and functional status of participants as well as quality of life. The disability dimension consists of 20 multiple choice items concerning difficulty in performing 8 common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and activities. Participants choose from 4 response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92 and 104
Reported as:
Mean · score on a scale
Change From Baseline in Health Assessment Questionnaire (HAQ-DI) Score Over Time
score on a scaleTocilizumab
Change at Week 12 (n=49)-0.2 ± 0.4
Change at Week 24 (n=46)-0.2 ± 0.4
Change at Week 36 (n=46)-0.1 ± 0.4
Change at Week 48 (n=45)0.0 ± 0.5
Change at Week 56 (n=44)-0.1 ± 0.6
Change at Week 68 (n=45)-0.2 ± 0.5
Change at Week 80 (n=45)-0.2 ± 0.5
Change at Week 92 (n=43)0.0 ± 0.6
Change at Week 104 (n=43)-0.1 ± 0.5

Adverse events

Collected over Up to 112 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab0/49 (0%)5/49 (10.2%)22/49 (44.9%)
Most frequent serious events
Most frequent serious events
EventTocilizumab
ArrhythmiaCardiac disorders1/49
HypertensionVascular disorders1/49
Cholecystitis acuteHepatobiliary disorders1/49
Hypertensive crisisVascular disorders1/49
PneumoniaRespiratory, thoracic and mediastinal disorders1/49
Jaw abscessMusculoskeletal and connective tissue disorders1/49
Most frequent other events
Most frequent other events
EventTocilizumab
Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders9/49
Alanine aminotransferase increasedInvestigations5/49
BronchitisInfections and infestations4/49
Aspartate aminotransferase increasedInvestigations3/49
DyslipidaemiaMetabolism and nutrition disorders3/49
NeutropeniaBlood and lymphatic system disorders3/49

Baseline characteristics

Full analysis set (FAS), includes all randomized participants enrolled in the study who received at least one dose of tocilizumab.

Age, Continuous
Age, Continuous(years)Tocilizumab
Mean53.3 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab
Female36
Male13
08

Study locations

12 sites
  • Ekaterinburg, 620102, Russian Federation
  • Moscow, 105203, Russian Federation
  • Moscow, 115522, Russian Federation
  • Moscow, 115682, Russian Federation
  • Moscow, 119049, Russian Federation
  • Moscow, 129327, Russian Federation
  • Ryazan, 390011, Russian Federation
  • Saint-Petersburg, 195067, Russian Federation
  • Saratov, 410002, Russian Federation
  • Tula, 300053, Russian Federation
  • Voronezh, 394066, Russian Federation
  • Yaroslavl, 150030, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2023, 8 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2012
First posted
Aug 14, 2012
Start
May 2012
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Results first posted
Dec 11, 2023
Last update
Dec 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01664598
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 14, 2012
Start date
May 2012
Primary completion
Jun 2015
Completion
Jun 2015
Results posted
Dec 11, 2023
Last update
Dec 11, 2023

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion